Immunotherapy

Neurodegenerative diseases

Therapeutic Approach:

Develop disease modifying ModuloDEEP declensional peptides for treating Parkinson’s disease and tauopathies such as progressive supranuclear palsy (PSP), mild cognitive impairment (MCI) and Alzheimer’s disease (AD).

Parkinson’s disease:

ModuloDEEP declensional peptides incorporating complete pattern of abnormal phosphorylated and tri-nitrated amino acid residues of α-synuclein.

  • Drive anti-inflammatory effect of compound and peptide derivatives on microglia
  • Induce antibodies specific for toxic species of α-synuclein, i.e., phosphorylated serine and nitrated tyrosines
  • Antibodies will clear toxic oligomers and protofibrils prior to Lewy body deposits

Tauopathies such as Progressive Supranuclear Palsy (PSP)

ModuloDEEP declensional peptides incorporating pattern of abnormally phosphorylated amino acid residues of tau protein.

  • Drive anti-inflammatory effect of compound and peptide derivatives on microglia
  • Induce antibodies specific for toxic species of tau, i.e., phosphorylated tau proteins and peptidic fragments
  • Antibodies will clear toxic oligomers and protofibrils prior to neurofibrillary tangle formation
ModuloDEEP for Parkinson's

Autoimmune diseases

Therapeutic Approach:

Develop disease modifying ModuloDEEP declensional peptides for treating orphan autoimmune diseases such as pemphigus vulgaris (PV) by inducing a tolerogenic immune response against specific regions of auto-antigens.

Pemphigus Vulgaris (PV)

ModuloDEEP declensional peptides of declensional epitopes of desmoglein 1 and desmoglein 3.

  • Control disease progression and reduce or eliminate chronic steroid therapy by specifically dampening autoimmune response against N-terminal regions of Dsg1 and Dsg3
  • Induce Regulatory T-cells
  • Induce Regulatory B-cells
  • Induce Anti-inflammatory monocytes